Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

CGEM Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Cullinan Therapeutics, Inc.NASDAQ: CGEM

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 2.1% from a year ago

Cash & equivalents stood at $75.08M at the end of Q1 FY2026, down 2.1% from a year earlier and down 15.0% from the prior quarter. Over 3 fiscal years it compounded at -17.3% a year.

Context

  • Cash & equivalents amounted to 18.6% of total assets at the end of Q1 FY2026, up 5.4 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -2.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$75.08M-15.0% QoQ
Last fiscal yearDec 2025
$88.33M+6.4% YoY
Year agoMar 2025
$76.66M-2.1% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.1%——
1 year+6.4%——
3-year CAGR-17.3%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
88.33M USD
Year-over-year change
+6.4%
4-year CAGR
+10.3%

Cash & Equivalents vs competitors

How CGEM compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -2.1% is the 8th highest of 11, against a peer median of +21.4%.
  • Cash & equivalents amounts to 18.6% of total assets for CGEM, versus a peer median of 22.8%.
CGEM Competitors
Cash & Equivalents for CGEM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NRIXNurix Therapeutics, Inc.Aug 2026$720.24M USD+818.2%+56.5%60.3%
LEGNLegend Biotech CorporationSep 2026$460.7M USD+65.2%+4.7%27.4%
IMTXImmatics N.V.Mar 2026€301.65M EUR+24.2%+32.5%55.5%
ADCTADC Therapeutics S.A.Mar 2026$231.01M USD+18.6%-7.1%79.2%
CGEMCullinan Therapeutics, Inc.Mar 2026$75.08M USD-2.1%-17.3%18.6%
MGNXMacroGenics, Inc.Mar 2026$66.52M USD-54.3%-19.3%30.5%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$62.1M USD+24.5%-34.7%17.8%
JANXJanux Therapeutics, Inc.Mar 2026$51.83M USD-29.7%+0.6%5.0%
XNCRXencor, Inc.Jun 2026$44.66M USD+0.5%+0.1%6.2%
ALXOALX Oncology Holdings Inc.Mar 2026$32.28M USD+56.6%-30.5%18.1%
CGENCompugen Ltd.Mar 2026$12.44M USD-14.7%+101.6%8.5%
Peer median (excluding CGEM) —+21.4%+0.3%22.8%

Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents59.77M156.15M98.43M83.01M88.33M
Short-term Investments230.69M311.14M368.63M315.97M289.56M
Net Receivables0003M0
Inventory00000
Other Current Assets07.18M13.12M12.69M8.86M
Total Current Assets296.56M474.47M480.19M414.67M386.76M
Property, Plant & Equipment (Net)77K5.3M3.53M2.35M3.05M
Goodwill00000
Intangible Assets00000
Long-term Investments140.4M80.88M0204.44M58.27M
Tax Assets00000
Other Non-current Assets147K459K459K366K297K
Total Non-current Assets140.62M86.65M3.99M207.16M61.62M
Total Assets437.19M561.12M484.18M621.82M448.37M
Account Payables3.17M2.66M2.49M1.68M841K
Short-term Debt0178K000
Tax Payables04.28M000
Deferred Revenue00000
Other Current Liabilities3.55M1.96M7.9M1.44M10.95M
Total Current Liabilities11.75M22.5M28.14M30.65M37.74M
Long-term Debt00001.9M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities65K0000
Total Non-current Liabilities65K3.59M2.15M849K1.9M
Total Liabilities11.81M26.09M30.29M31.5M39.64M
Common Stock4K5K4K6K6K
Retained Earnings(158.91M)(47.7M)(200.86M)(368.24M)(588.12M)
Accumulated OCI(838K)(2.6M)(129K)(133K)1.02M
Other Stockholders Equity00000
Minority Interest403K0192K00
Total Equity425.37M535.03M453.9M590.33M408.73M
Total Debt05.19M3.59M2.15M2.68M
Net Debt(59.77M)(150.96M)(94.84M)(80.85M)(85.65M)

Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Intrinsic Alpha fair value

Locked

Current Price

$9.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.